# RAAS Inhibitor Drugs in Dialysis Patients

Study · id `cardio:ct-nct01635387` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01635387](<https://clinicaltrials.gov/study/NCT01635387>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01635387

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

## Technical summary

Registry record NCT01635387. Randomized; triple masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2012-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT01635387, source copy `cardio:ctgov-nct01635387-2012-07-09`, retrieved 2026-10-26)
- Start date: 2010-02 (registry gives no type) (ClinicalTrials.gov record NCT01635387, source copy `cardio:ctgov-nct01635387-2012-07-09`, retrieved 2026-10-26)
- Primary completion: 2012-09 (anticipated) (ClinicalTrials.gov record NCT01635387, source copy `cardio:ctgov-nct01635387-2012-07-09`, retrieved 2026-10-26)
- Completion: 2012-09 (anticipated) (ClinicalTrials.gov record NCT01635387, source copy `cardio:ctgov-nct01635387-2012-07-09`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01635387-2012-07-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: RAAS Inhibitor Drugs in Dialysis Patients
- Condition: Hypertension
- Condition: End Stage Renal Disease
- Intervention (Drug): aliskiren
- Lead sponsor: University of Campania Luigi Vanvitelli
- Lead sponsor class: OTHER
- Collaborator: IRCCS San Raffaele
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Campania Luigi Vanvitelli (`cardio:org-university-of-campania-luigi-vanvitelli`)
- Registry lists this organization as a collaborator: IRCCS San Raffaele (`cardio:org-irccs-san-raffaele`)

## Provenance

Content hash: 9ec8ace934fbc7dbd9a9c92397785dff3a616cad2e8033c6bbae1b6bc634b942
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
